NewswireToday - /newswire/ -
Needham, MA, United States, 2012/10/24 - Latest speaker confirmed: John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics - TriConference.com / CHICorporate.com.
CHI’s 2nd annual Targeting Cancer Stem Cells: Promising New Therapeutics for Oncology symposium will once again be a part of the Molecular Medicine Tri-Conference taking place at the Moscone North Convention Center in San Francisco, CA. Presentations will highlight achievements in basic science enhancing our understanding of cancer stem cells, and advances in the discovery and development of novel therapeutics making their way to the clinic. Presentations will focus on the unique challenges of working with CSCs, from characterizing cell populations to the development of screening assays, identification of druggable targets and pathways, validation in pre-clinical models, and translation to the clinic.
CHI just confirmed the participation of Dr. John S. Yu (Cedars-Sinai Medical Center / ImmunoCellular Therapeutics) who will deliver a presentation on “Active Immunotherapy for Cancer Stem Cells.” ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company focused on developing products for the treatment of brain and other cancers that harness the native immune system to attack CSCs without harming healthy tissue. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.
Dr. Yu is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon, Dr. Yu's clinical focus is on the treatment of malignant and benign brain and spinal tumors. He is also conducting extensive research in immune and gene therapy for brain tumors. He has also done extensive research in the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases. He was inducted into Castle and Connelly's America's Top Doctors in 2005. Dr. Yu has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery.
Additional companies presenting:
• Cellerant Therapeutics, Inc.
• Dainippon Sumitomo Pharma Group
• ETH Zurich
• Genentech, Inc.
• Macrogenics, Inc.
• McMaster University
• OncoMed Pharmaceuticals
• The Mount Sinai School of Medicine
• Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center
• University of California Los Angeles
• University of Michigan Comprehensive Cancer Center
• University of Texas Southwestern Medical Center
• Verastem, Inc.
To view the agenda and to register, please visit TriConference.com/.
About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.